Sep 2, 2020 SOURCE: PR NewsWire

Global Malignant Pleural Mesothelioma (MPM) Epidemiology and Market Assessment 2017-2030

DUBLIN, Sept. 2, 2020 /PRNewswire/ -- The "Malignant Pleural Mesothelioma (MPM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The report delivers an in-depth understanding of the disease, historical and forecasted MPM epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidemiology

The MPM epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The MPM epidemiology data are studied through MPM possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted MPM epidemiology [segmented as Total Incidence of Mesothelioma, Total Incident Cases of MPM, Total Incident Cases of MPM Segmented by Age and Gender, Total Type-specific Cases of MPM, Total Incident Cases of MPM by Stages, and Treated Patient Pool of MPM] scenario of MPM in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Detailed Epidemiology Segmentation

    --  The total Incident cases of MPM in the 7MM were observed to be 11,431
        cases in 2017 which are estimated to decline during the study period
        (2017-2030
    --  Mesothelioma incidence rates in most of the 7MM countries (except Spain
        and Japan) are in the declining trend due to reduced population-wide
        exposure to asbestos.
    --  In EU-5 countries, the highest number of incident cases of MPM was found
        in the United Kingdom with 2,495 cases in 2017, followed by Germany and
        Italy.
    --  Epithelial mesothelioma cells are the most common type of MPM and
        respond the best to treatment
    --  In age-specific cases of MPM, the most number of cases were observed in
        elder people (more than 80% cases in people age 60 years and above)
        because mesothelioma carries an unusually long latency period of 20 to
        50 years.

Scope of the Report

    --  The MPM report covers a detailed overview explaining its causes,
        symptoms, classification, pathophysiology, diagnosis, and treatment
        patterns.
    --  The MPM Report and Model provide an overview of the risk factors and
        global trends of MPM in the seven major markets (7MM: United States,
        Germany, France, Italy, Spain, and the United Kingdom, and Japan).
    --  The report provides insight about the historical and forecasted patient
        pool of MPM in seven major markets covering the United States, EU5
        (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
    --  The report helps to recognize the growth opportunities in the 7MM with
        respect to the patient population.
    --  The report assesses the disease risk and burden and highlights the unmet
        needs of MPM.
    --  The report provides the segmentation of the MPM epidemiology by total
        Incidence of MPM in the 7MM.
    --  The report provides the segmentation of the MPM epidemiology by Age and
        Gender in the 7MM.
    --  The report provides the segmentation of the MPM epidemiology by Type and
        Stages in the 7MM.
    --  The report provides the segmentation of the MPM epidemiology by Treated
        Patient Pool of MPM in the 7MM.

Report Highlights

    --  11-Year Forecast of MPM epidemiology
    --  7MM Coverage
    --  Total Incident Cases of Mesothelioma in the 7MM
    --  Total Incident Cases of MPM in the 7MM
    --  Incident Cases of MPM according to segmentation: Age, Gender, Types, and
        Stages
    --  Treated cases of MPM

KOL Views

We interview, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over MPM scenario of the indications.

Key Questions Answered

    --  What will be the growth opportunities in the 7MM with respect to the
        patient population pertaining to MPM ?
    --  What are the key findings pertaining to the Malignant Pleural
        Mesothelioma epidemiology across the 7MM and which country will have the
        highest number of patients during the study period (2017-2030)?
    --  What would be the total number of patients of Malignant Pleural
        Mesothelioma across the 7MM during the study period (2017-2030)?
    --  Among the EU5 countries, which country will have the highest number of
        patients during the study period (2017-2030)?
    --  At what CAGR the patient population is expected to grow in the 7MM
        during the study period (2017-2030)?
    --  What are the various recent and upcoming events which are expected to
        improve the diagnosis of Malignant Pleural Mesothelioma?
    --  What % of MPM patients diagnosed with the most advanced stage of cancer
        at diagnosis? And what % of patients with local or regional stage are
        progressing to distant stage?

Reasons to Buy

    --  Develop business strategies by understanding the trends shaping and
        driving the global MPM market
    --  Quantify patient populations in the global MPM market to improve product
        design, pricing, and launch plans
    --  Organize sales and marketing efforts by identifying the age groups and
        sex that present the best opportunities for MPM therapeutics in each of
        the markets covered
    --  Understand the magnitude of MPM population by its severity
    --  The MPM epidemiology report and model were written and developed by
        Masters and PhD level epidemiologists
    --  The MPM Epidemiology Model developed by the publisher is easy to
        navigate, interactive with dashboards, and epidemiology based with
        transparent and consistent methodologies. Moreover, the model supports
        data presented in the report and showcases disease trends over 11-year
        forecast period using reputable sources

Key Assessments

    --  Patient Segmentation
    --  Disease Risk and Burden
    --  Risk of disease by the segmentation
    --  Factors driving growth in a specific patient population

Geographies Covered

    --  The United States
    --  EU5 (Germany, France, Italy, Spain, and the United Kingdom)
    --  Japan

Study Period: 2017-2030

Total Incident cases of MPM in the United States was assessed to be 2,627 in 2017, and are expected to decline during the study period. Among the European 5 countries, the United Kingdom had the highest Incident population of MPM. On the other hand, Spain had the lowest incident cases of MPM in 2017.

For more information about this report visit https://www.researchandmarkets.com/r/y8q15

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-malignant-pleural-mesothelioma-mpm-epidemiology-and-market-assessment-2017-2030-301122980.html

SOURCE Research and Markets